These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 17485906)
1. Recent perspectives of endocrine therapy for breast cancer. Utsumi T; Kobayashi N; Hanada H Breast Cancer; 2007; 14(2):194-9. PubMed ID: 17485906 [TBL] [Abstract][Full Text] [Related]
2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Goel S; Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328 [TBL] [Abstract][Full Text] [Related]
3. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Carlson RW; Henderson IC Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531 [TBL] [Abstract][Full Text] [Related]
4. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Michaud LB; Buzdar AU Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Mathew A; Davidson NE Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743 [TBL] [Abstract][Full Text] [Related]
6. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time? Montagna E; Cancello G; Colleoni M Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877 [TBL] [Abstract][Full Text] [Related]
7. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R; J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825 [TBL] [Abstract][Full Text] [Related]
8. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Tan SH; Wolff AC Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122 [TBL] [Abstract][Full Text] [Related]
9. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661 [TBL] [Abstract][Full Text] [Related]
10. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834 [TBL] [Abstract][Full Text] [Related]
11. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065 [TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681 [TBL] [Abstract][Full Text] [Related]
13. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. Conte B; Poggio F; Del Mastro L Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603 [TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Gibson LJ; Dawson C; Lawrence DH; Bliss JM Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488 [TBL] [Abstract][Full Text] [Related]
15. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Buzdar AU Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330 [TBL] [Abstract][Full Text] [Related]
16. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC]. Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. Carlson RW; Hudis CA; Pritchard KI; ; ; J Natl Compr Canc Netw; 2006 Nov; 4(10):971-9. PubMed ID: 17112447 [TBL] [Abstract][Full Text] [Related]
18. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. Hackshaw A; Baum M; Fornander T; Nordenskjold B; Nicolucci A; Monson K; Forsyth S; Reczko K; Johansson U; Fohlin H; Valentini M; Sainsbury R J Natl Cancer Inst; 2009 Mar; 101(5):341-9. PubMed ID: 19244174 [TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer. Iwase H; Yamamoto Y Int J Clin Oncol; 2015 Apr; 20(2):253-61. PubMed ID: 25673474 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Bao T; Davidson NE Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]